Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
1(14%)
Results Posted
75%(3 trials)
Terminated
2(29%)

Phase Distribution

Ph phase_1
2
29%
Ph phase_3
1
14%
Ph phase_2
4
57%

Phase Distribution

2

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
4(57.1%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(4)
Terminated(2)

Detailed Status

Completed4
Terminated2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (28.6%)
Phase 24 (57.1%)
Phase 31 (14.3%)

Trials by Status

active_not_recruiting114%
terminated229%
completed457%

Recent Activity

1 active trials
Showing 5 of 7
active_not_recruitingphase_2

Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]

NCT03504163
completedphase_1

Pembrolizumab in Combination With CRT for LA-SCCHN

NCT02586207
completedphase_3

Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)

NCT03783078
completedphase_2

Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma

NCT02736266
terminatedphase_2

Checkpoint Blockade in COVID-19 Pandemic

NCT04335305
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT03504163Phase 2

Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]

Active Not Recruiting
NCT02586207Phase 1

Pembrolizumab in Combination With CRT for LA-SCCHN

Completed
NCT03783078Phase 3

Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)

Completed
NCT02736266Phase 2

Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma

Completed
NCT04335305Phase 2

Checkpoint Blockade in COVID-19 Pandemic

Terminated
NCT03111732Phase 2

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)

Completed
NCT02346955Phase 1

Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)

Terminated

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7